Patients are routinely prescribed anticoagulant or antiplatelet therapy after tissue plasminogen activator (tPA) treatment [14] This reduces the risk of recurrent ischemic stroke, but inversely increases the risk of developing HT [15]. The gene discussed is PLAT; the disease is hematocrit.